AU680241B2 - Xanthine derivatives as adenosine A1 receptor antagonists - Google Patents

Xanthine derivatives as adenosine A1 receptor antagonists Download PDF

Info

Publication number
AU680241B2
AU680241B2 AU62968/94A AU6296894A AU680241B2 AU 680241 B2 AU680241 B2 AU 680241B2 AU 62968/94 A AU62968/94 A AU 62968/94A AU 6296894 A AU6296894 A AU 6296894A AU 680241 B2 AU680241 B2 AU 680241B2
Authority
AU
Australia
Prior art keywords
dione
dipropyl
purine
dihydro
yield
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU62968/94A
Other languages
English (en)
Other versions
AU6296894A (en
Inventor
Mark W. Dudley
Janice M. Hitchcock
Norton P. Peet
Stephen M Sorenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Publication of AU6296894A publication Critical patent/AU6296894A/en
Application granted granted Critical
Publication of AU680241B2 publication Critical patent/AU680241B2/en
Assigned to MERRELL PHARMACEUTICALS INC. reassignment MERRELL PHARMACEUTICALS INC. Request to Amend Deed and Register Assignors: MERRELL DOW PHARMACEUTICALS INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU62968/94A 1993-02-26 1994-01-27 Xanthine derivatives as adenosine A1 receptor antagonists Ceased AU680241B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2350193A 1993-02-26 1993-02-26
US023501 1993-02-26
PCT/US1994/001009 WO1994019349A1 (en) 1993-02-26 1994-01-27 Xanthine derivatives as adenosine a1 receptor antagonists

Publications (2)

Publication Number Publication Date
AU6296894A AU6296894A (en) 1994-09-14
AU680241B2 true AU680241B2 (en) 1997-07-24

Family

ID=21815459

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62968/94A Ceased AU680241B2 (en) 1993-02-26 1994-01-27 Xanthine derivatives as adenosine A1 receptor antagonists

Country Status (19)

Country Link
US (1) US5840729A (enExample)
EP (1) EP0686155B1 (enExample)
JP (1) JPH08512281A (enExample)
KR (1) KR100315898B1 (enExample)
CN (1) CN1041418C (enExample)
AT (1) ATE169019T1 (enExample)
AU (1) AU680241B2 (enExample)
CA (1) CA2155130C (enExample)
DE (1) DE69412073T2 (enExample)
DK (1) DK0686155T3 (enExample)
ES (1) ES2120025T3 (enExample)
HU (1) HUT72677A (enExample)
IL (1) IL108750A (enExample)
MX (1) MX9401406A (enExample)
NO (1) NO311920B1 (enExample)
NZ (1) NZ262984A (enExample)
TW (1) TW261532B (enExample)
WO (1) WO1994019349A1 (enExample)
ZA (1) ZA941176B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041237A1 (en) * 1997-03-18 1998-09-24 Fujisawa Pharmaceutical Co., Ltd. Preventives and remedies for hyperphosphatemia
IL139787A0 (en) 1998-06-02 2002-02-10 Osi Pharm Inc PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
DE60234118D1 (de) 2001-11-30 2009-12-03 Osi Pharm Inc Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen
BR0215202A (pt) 2001-12-20 2004-10-13 Osi Pharm Inc Compostos antagonistas seletivos a2b de pirimidina, sua sìntese e uso
AU2003239472A1 (en) * 2002-05-15 2003-12-02 Genzyme Corporation Synthesis of benzonitriles and benzimidates
WO2004086047A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1)
JPWO2005056016A1 (ja) * 2003-12-09 2007-07-05 協和醗酵工業株式会社 高次脳機能障害の予防および／または治療剤
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2007095161A2 (en) * 2006-02-14 2007-08-23 New York University Methods and compositions for treating disorders associated with increased bone turnover and osteopenia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449175A2 (en) * 1990-03-26 1991-10-02 Merrell Pharmaceuticals Inc. Selective adenosine receptor agents
EP0503563A2 (en) * 1991-03-12 1992-09-16 Merrell Pharmaceuticals Inc. Novel 8-substituted purines as selective adenosine receptor agents
AU637990B2 (en) * 1988-12-22 1993-06-17 Boehringer Ingelheim International Gmbh Xanthine derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
JPH0455150A (ja) * 1990-06-22 1992-02-21 Takata Kk 助手席用エアバッグ装置
US5087827A (en) * 1991-02-11 1992-02-11 Tektronix, Inc. Variable voltage transition circuit
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU637990B2 (en) * 1988-12-22 1993-06-17 Boehringer Ingelheim International Gmbh Xanthine derivatives
EP0449175A2 (en) * 1990-03-26 1991-10-02 Merrell Pharmaceuticals Inc. Selective adenosine receptor agents
EP0503563A2 (en) * 1991-03-12 1992-09-16 Merrell Pharmaceuticals Inc. Novel 8-substituted purines as selective adenosine receptor agents

Also Published As

Publication number Publication date
ZA941176B (en) 1994-09-20
US5840729A (en) 1998-11-24
HU9502495D0 (en) 1995-10-30
IL108750A (en) 2000-09-28
DK0686155T3 (da) 1999-02-01
ES2120025T3 (es) 1998-10-16
DE69412073D1 (de) 1998-09-03
MX9401406A (es) 1994-08-31
HUT72677A (en) 1996-05-28
NO311920B1 (no) 2002-02-18
CN1118599A (zh) 1996-03-13
DE69412073T2 (de) 1999-02-18
CN1041418C (zh) 1998-12-30
JPH08512281A (ja) 1996-12-24
ATE169019T1 (de) 1998-08-15
NZ262984A (en) 1997-05-26
NO953353L (no) 1995-08-25
IL108750A0 (en) 1994-05-30
CA2155130A1 (en) 1994-09-01
EP0686155A1 (en) 1995-12-13
KR100315898B1 (ko) 2002-02-28
AU6296894A (en) 1994-09-14
WO1994019349A1 (en) 1994-09-01
CA2155130C (en) 1994-09-01
EP0686155B1 (en) 1998-07-29
NO953353D0 (no) 1995-08-25
TW261532B (enExample) 1995-11-01

Similar Documents

Publication Publication Date Title
DK169271B1 (da) 8-Phenylxanthinderivater, fremgansmåde til fremstilling heraf, farmaceutisk præparat indeholdende en sådan forbindelse, samt en sådan forbindelse til anvendelse til terapi
KR100884818B1 (ko) 아데노신 Ａ２ａ 수용체의 리간드로서 유용한트리아졸릴-이미다조피리딘 및 트리아졸릴퓨린의 유도체,및 약제로서 그의 용도
EP0607607B1 (en) Xanthine derivatives
AU746590B2 (en) Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US6545000B1 (en) [1,2,4]triazolo[1,5-c]pyrimidine derivatives
JPH06211856A (ja) パーキンソン氏病治療剤
EP0565377B1 (en) Therapeutic agents for use in the treatment of Parkinson's Disease
US5840729A (en) Xanthine derivatives as adenosine A1 receptor antagonists
US6376472B1 (en) Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
EP1347981B1 (en) Condensed purine derivatives as a 1 adenosine receptor antagonists
AU2002219977A1 (en) Condensed purine derivatives as A1 adenosine receptor antagonists
US5047534A (en) Selective adenosine receptor agents
AU2007288312A1 (en) KW-3902 conjugates that do not cross the blood-brain barrier
AU676323B2 (en) 8-substituted xanthines as selective adenosine receptor agents
JPWO2000017201A1 (ja) ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
HK1059927B (en) Condensed purine derivatives as a1 adenosine receptor antagonists

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: MERRELL PHARMACEUTICALS INC.

Free format text: FORMER NAME WAS: MERRELL DOW PHARMACEUTICALS INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired